<?xml version='1.0' encoding='utf-8'?>
<document id="12403641"><sentence text="Clinical pharmacokinetics of tegaserod, a serotonin 5-HT(4) receptor partial agonist with promotile activity."><entity charOffset="29-38" id="DDI-PubMed.12403641.s1.e0" text="tegaserod" /><entity charOffset="42-51" id="DDI-PubMed.12403641.s1.e1" text="serotonin" /><pair ddi="false" e1="DDI-PubMed.12403641.s1.e0" e2="DDI-PubMed.12403641.s1.e0" /><pair ddi="false" e1="DDI-PubMed.12403641.s1.e0" e2="DDI-PubMed.12403641.s1.e1" /></sentence><sentence text="Tegaserod, a selective serotonin (5-hydroxytryptamine; 5-HT) 5-HT(4) receptor partial agonist, is indicated in patients with irritable bowel syndrome (IBS) who identify abdominal pain or discomfort and constipation as their predominant symptoms"><entity charOffset="0-9" id="DDI-PubMed.12403641.s2.e0" text="Tegaserod" /><entity charOffset="23-32" id="DDI-PubMed.12403641.s2.e1" text="serotonin" /><entity charOffset="34-53" id="DDI-PubMed.12403641.s2.e2" text="5-hydroxytryptamine" /><entity charOffset="55-59" id="DDI-PubMed.12403641.s2.e3" text="5-HT" /><entity charOffset="61-64" id="DDI-PubMed.12403641.s2.e4" text="5-HT" /><pair ddi="false" e1="DDI-PubMed.12403641.s2.e0" e2="DDI-PubMed.12403641.s2.e0" /><pair ddi="false" e1="DDI-PubMed.12403641.s2.e0" e2="DDI-PubMed.12403641.s2.e1" /><pair ddi="false" e1="DDI-PubMed.12403641.s2.e0" e2="DDI-PubMed.12403641.s2.e2" /><pair ddi="false" e1="DDI-PubMed.12403641.s2.e0" e2="DDI-PubMed.12403641.s2.e3" /><pair ddi="false" e1="DDI-PubMed.12403641.s2.e0" e2="DDI-PubMed.12403641.s2.e4" /><pair ddi="false" e1="DDI-PubMed.12403641.s2.e1" e2="DDI-PubMed.12403641.s2.e1" /><pair ddi="false" e1="DDI-PubMed.12403641.s2.e1" e2="DDI-PubMed.12403641.s2.e2" /><pair ddi="false" e1="DDI-PubMed.12403641.s2.e1" e2="DDI-PubMed.12403641.s2.e3" /><pair ddi="false" e1="DDI-PubMed.12403641.s2.e1" e2="DDI-PubMed.12403641.s2.e4" /><pair ddi="false" e1="DDI-PubMed.12403641.s2.e2" e2="DDI-PubMed.12403641.s2.e2" /><pair ddi="false" e1="DDI-PubMed.12403641.s2.e2" e2="DDI-PubMed.12403641.s2.e3" /><pair ddi="false" e1="DDI-PubMed.12403641.s2.e2" e2="DDI-PubMed.12403641.s2.e4" /><pair ddi="false" e1="DDI-PubMed.12403641.s2.e3" e2="DDI-PubMed.12403641.s2.e3" /><pair ddi="false" e1="DDI-PubMed.12403641.s2.e3" e2="DDI-PubMed.12403641.s2.e4" /></sentence><sentence text=" Tegaserod at dosages of 1 to 12 mg/day exerts pharmacodynamic actions in the upper and the lower gastrointestinal tract, accelerating small bowel and colonic transit in patients with IBS"><entity charOffset="1-10" id="DDI-PubMed.12403641.s3.e0" text="Tegaserod" /></sentence><sentence text=" Tegaserod is rapidly absorbed following oral administration; peak plasma concentrations (C(max)) are reached after approximately 1 hour"><entity charOffset="1-10" id="DDI-PubMed.12403641.s4.e0" text="Tegaserod" /></sentence><sentence text=" Absolute bioavailability is about 10% under fasted conditions" /><sentence text=" Food reduces the bioavailability of tegaserod by 40 to 65% and the C(max) by 20 to 40%"><entity charOffset="37-46" id="DDI-PubMed.12403641.s6.e0" text="tegaserod" /></sentence><sentence text=" Systemic exposure to tegaserod is not significantly altered at neutral gastric pH compared with the fasted state (pH 2)"><entity charOffset="22-31" id="DDI-PubMed.12403641.s7.e0" text="tegaserod" /></sentence><sentence text=" Tegaserod is approximately 98% bound to plasma proteins, primarily to alpha(1)-acid glycoprotein, and has a volume of distribution at steady-state of 368 +/- 223L"><entity charOffset="1-10" id="DDI-PubMed.12403641.s8.e0" text="Tegaserod" /></sentence><sentence text=" Tegaserod is metabolised mainly via two pathways"><entity charOffset="1-10" id="DDI-PubMed.12403641.s9.e0" text="Tegaserod" /></sentence><sentence text=" The first is a presystemic acid-catalysed hydrolysis in the stomach followed by oxidation and conjugation which produces the main metabolite of tegaserod, 5-methoxyindole-3-carboxylic acid glucuronide (M 29"><entity charOffset="16-32" id="DDI-PubMed.12403641.s10.e0" text="presystemic acid" /><entity charOffset="145-154" id="DDI-PubMed.12403641.s10.e1" text="tegaserod" /><entity charOffset="156-201" id="DDI-PubMed.12403641.s10.e2" text="5-methoxyindole-3-carboxylic acid glucuronide" /><pair ddi="false" e1="DDI-PubMed.12403641.s10.e0" e2="DDI-PubMed.12403641.s10.e0" /><pair ddi="false" e1="DDI-PubMed.12403641.s10.e0" e2="DDI-PubMed.12403641.s10.e1" /><pair ddi="false" e1="DDI-PubMed.12403641.s10.e0" e2="DDI-PubMed.12403641.s10.e2" /><pair ddi="false" e1="DDI-PubMed.12403641.s10.e1" e2="DDI-PubMed.12403641.s10.e1" /><pair ddi="false" e1="DDI-PubMed.12403641.s10.e1" e2="DDI-PubMed.12403641.s10.e2" /></sentence><sentence text="0)" /><sentence text=" This metabolite has negligible affinity for 5-HT(4) receptors and is devoid of promotile activity"><entity charOffset="45-89" id="DDI-PubMed.12403641.s12.e0" text="5-HT" /></sentence><sentence text=" The second is direct glucuronidation which leads to generation of three isomeric N-glucuronides"><entity charOffset="82-96" id="DDI-PubMed.12403641.s13.e0" text="N-glucuronides" /></sentence><sentence text=" The plasma clearance of tegaserod is 77 +/- 15 L/h, with an estimated terminal half-life of 11 +/- 5 hours following intravenous administration"><entity charOffset="25-34" id="DDI-PubMed.12403641.s14.e0" text="tegaserod" /></sentence><sentence text=" Approximately two-thirds of the orally administered dose of tegaserod is excreted unchanged in faeces, with the remainder excreted in urine, primarily as M 29"><entity charOffset="61-70" id="DDI-PubMed.12403641.s15.e0" text="tegaserod" /></sentence><sentence text="0" /><sentence text=" The pharmacokinetics of tegaserod are dose-proportional over the range 2 to 12mg given twice daily for 5 days, with no relevant accumulation"><entity charOffset="25-34" id="DDI-PubMed.12403641.s17.e0" text="tegaserod" /></sentence><sentence text=" The pharmacokinetics of tegaserod in patients with IBS are comparable to those in healthy individuals, and similar between men and women"><entity charOffset="25-34" id="DDI-PubMed.12403641.s18.e0" text="tegaserod" /></sentence><sentence text=" No dosage adjustment is required in elderly patients or those with mild to moderate hepatic or renal impairment" /><sentence text=" Tegaserod should not be used in patients with severe hepatic or renal impairment"><entity charOffset="1-10" id="DDI-PubMed.12403641.s20.e0" text="Tegaserod" /></sentence><sentence text=" No clinically relevant drug-drug interactions with tegaserod have been identified"><entity charOffset="52-61" id="DDI-PubMed.12403641.s21.e0" text="tegaserod" /></sentence><sentence text=" In vivo drug-drug interaction studies with theophylline [a cytochrome P450 (CYP) 1A2 prototype substrate], dextromethorphan (a CYP2D6 prototype substrate), digoxin, warfarin and oral contraceptives have indicated no clinically relevant interactions and no requirement for dosage adjustment"><entity charOffset="44-56" id="DDI-PubMed.12403641.s22.e0" text="theophylline" /><entity charOffset="108-124" id="DDI-PubMed.12403641.s22.e1" text="dextromethorphan" /><entity charOffset="157-164" id="DDI-PubMed.12403641.s22.e2" text="digoxin" /><pair ddi="false" e1="DDI-PubMed.12403641.s22.e0" e2="DDI-PubMed.12403641.s22.e0" /><pair ddi="false" e1="DDI-PubMed.12403641.s22.e0" e2="DDI-PubMed.12403641.s22.e1" /><pair ddi="false" e1="DDI-PubMed.12403641.s22.e0" e2="DDI-PubMed.12403641.s22.e2" /><pair ddi="false" e1="DDI-PubMed.12403641.s22.e1" e2="DDI-PubMed.12403641.s22.e1" /><pair ddi="false" e1="DDI-PubMed.12403641.s22.e1" e2="DDI-PubMed.12403641.s22.e2" /></sentence><sentence text="" /></document>